Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06222593 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study Identification, Study Status, Oversightv6
  2. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Jul 1, 2025 to Jul 1, 2026
    • Study sites: 0 to 1
    • Study completion date: Jul 1, 2026 to Jul 1, 2027
    • Start date changed from estimate of Oct 2024 to Oct 1, 2024
  3. Start date: Jun 1, 2024 to Oct 2024v4
  4. Start date: Apr 1, 2024 to Jun 1, 2024v3
  5. Start date: Jan 22, 2024 to Apr 1, 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.
Trial Details
NCT Number NCT06222593
Lead Sponsor State University of New York at Buffalo
Conditions
(from sponsor)		 Carcinoma, Renal Cell
Related terms Carcinoma, Renal Cell
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov